Herpes Zoster Vaccine
-
Subject Areas on Research
- A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.
- A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
- Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources.
- Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
- Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia.
- Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.
- Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
- Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults.
- Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
- Evaluation of two frailty indices, with practical application in a vaccine clinical trial.
- Herpes Zoster Vaccination: Controversies and Common Clinical Questions.
- Herpes Zoster.
- Long-term persistence of zoster vaccine efficacy.
- Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.
- Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.
- Perspective on live varicella vaccine.
- Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.
- Safety of zoster vaccine in elderly adults following documented herpes zoster.
- The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
- The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.
- The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.
- The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.
- The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.
- Update on immunizations in adults.
- Vaccination against Herpes Zoster and Postherpetic Neuralgia.
- Vaccination against herpes zoster in developed countries: state of the evidence.
- Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
- Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.